Stemline Therapeutics, Inc. (NASDAQ:STML) Q1 2019 Earnings Conference Call Transcript

May 10, 2019 • 08:00 am ET


Stemline Therapeutics, Inc. (NASDAQ:STML) Q1 2019 Earnings Conference Call Transcript


Loading Event

Loading Transcript


Good day, and welcome to the Stemline earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. Ken Hoberman. Please go ahead, sir.

Kenneth Hoberman

Thank you. Good morning and welcome to today's conference call to discuss our first quarter 2019 financial results. With me on today's call are members of Stemline's executive management team, including Ivan Bergstein, our Chief Executive Officer; David Gionco, our Chief Accounting Officer; and Robert Francomano, our Senior Vice President and Global Head of Commercial. After our remarks, we'll open the call to take your questions.

As a reminder, we may be making forward-looking statements. Our forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to differ materially from our forecasts. A detailed description of these risks can be found in the forward-looking statements in Risk Factors section of our annual report on Form 10-K for the year ended December 31st, 2018, and our other reports filed with the SEC.

With that, I will now turn over the call to Ivan Bergstein, our CEO. Ivan, the floor is yours.

Ivan Bergstein

Thank you, Ken, and good morning to everyone. The past few months have been transformational for Stemline as ELZONRIS was approved by the FDA and launched in the U.S. for the treatment of adult and pediatric patients, two years and older with blastic plasmacytoid dendritic cell neoplasm or BPDCN. ELZONRIS is the first treatment ever approved for BPDCN and the first CD123 targeted agent ever approved.

Also, as many of you've seen, the New England Journal of Medicine published the ELZONRIS pivotal results in its April 25th issue, highlighting the increase in global awareness and recognition of BPDCN across the entire medical community. We're extremely proud and gratified to bring to patient's with BPDCN a new and effective treatment. And we are pleased with the strong initial uptake and adoption patterns we are seeing in the first quarter of launch.

Our Global Head of Commercial, Robert Francomano, will now provide further details on our launch. Robert?

Robert Francomano

Thank you, Ivan. I'm very pleased to announce that net sales of ELZONRIS were $5.05 million in our first quarter of launch. These encouraging results are the culmination of a concerted customer-facing effort between our marketing, sales, access and reimbursement and medical affairs teams. Our territory managers have had many impactful interactions with health care providers and institutions and sharing that ELZONRIS and BPDCN are kept top of mind.

These health care provider interactions involving product and disease education are broad institution-wide calls targeting hematologist, oncologist, transplanters, dermats as well as the hempath and dermpath communities. The team is focused on demonstrating the clinical benefit and value proposition of ELZONRIS as the new standard of care for BPDCN to ensure its rightful place in the treatment paradigm. Alongside the ELZONRIS directed product promotion, we continue to improve the accuracy and speed of diagnosis of patients with BPDCN by raising the awareness of the disease